OncologyEducation presents MedOncNow
In this episode, Dr. Barb Melosky takes us through practical aspects of using HER2 targeted agents in HER2 altered advanced NSCLC. This is particularly timely given we now have access through company sponsored SAP programs for both Zongertinib and Sevabertinib.
21 Episoder
Kommentarer
0Vær den første til å kommentere
Registrer deg nå og bli medlem av OncologyEducation presents MedOncNow sitt community!